S-1: Kenvue Files for Secondary Offering as Johnson & Johnson Exits Stake

Kenvue Inc. files an S-1 registration statement for a secondary offering of 182,329,550 shares of common stock, as Johnson & Johnson plans to fully divest its remaining stake through a debt-for-equity exchange.

Summary

• Kenvue Inc. has filed a Form S-1 registration statement for a secondary offering of 182,329,550 shares of its common stock.
• The offering involves shares currently held by Johnson & Johnson (J&J).
• J&J intends to exchange these shares for its outstanding indebtedness held by Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC (the debt-for-equity exchange parties).
• Following the exchange, the debt-for-equity exchange parties will offer the shares to underwriters for cash.
• The completion of the debt-for-equity exchange is contingent upon the settlement of the offering.
• Upon completion of this offering, Johnson & Johnson will no longer own any shares of Kenvue's common stock.
• Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as underwriters for this offering.
• Kenvue will not receive any proceeds from the sale of shares in this offering.
• The company had $15.4 billion in net sales in 2023.
• Kenvue operates in three segments: Self Care, Skin Health and Beauty, and Essential Health.
• The company's brands include Tylenol, Neutrogena, Listerine, Johnsons, BAND-AID Brand, Aveeno, Zyrtec, and Nicorette.
• Approximately half of Kenvue's net sales were generated outside North America in 2023.
• Kenvue was separated from Johnson & Johnson in August 2023.
• The company's common stock is listed on the New York Stock Exchange under the symbol KVUE.
• A quarterly cash dividend of $0.20 per share was declared on April 25, 2024, payable on May 22, 2024.

Sentiment

Score: 6

Explanation: The document is neutral. It primarily outlines the details of a secondary offering and the exit of Johnson & Johnson from Kenvue's shareholder structure. While it mentions risks, it also highlights Kenvue's strengths and future outlook.

Positives

• The completion of the separation from Johnson & Johnson allows Kenvue to operate as a fully independent public company.
• Kenvue has a diversified portfolio of well-known consumer health brands.
• The company has a global presence with approximately half of its net sales generated outside North America.
• Kenvue intends to continue paying a quarterly cash dividend.
• The company has a comprehensive environmental, social and governance (ESG) strategy.

Negatives

• Kenvue will not receive any proceeds from the sale of shares in this offering.
• The stock price of Kenvue's common stock may fluctuate significantly.
• The company faces substantial competitive pressures.
• Kenvue is subject to restrictions on its business, potential tax-related liabilities, and potential tax-related indemnification obligations to Johnson & Johnson.
• The company has debt obligations that could adversely affect its business, results of operations, or financial condition.

Risks

• Damage to the company's reputation and the reputation of its brands could impact brand loyalty.
• The company faces substantial competitive pressures from various sources.
• The company's ability to innovate and respond to market trends is crucial.
• The company's marketing efforts may be costly and inefficient.
• Expanding global operations requires significant resources and expenses.
• The company may face challenges in implementing its digital-first strategy.
• The company relies on third parties in many aspects of its business.
• Disruptions to manufacturing or supplier operations could adversely affect the business.
• Inflationary pressures and related volatility in the cost of raw materials could impact the business.
• Information security incidents could result in reputational damage and operational disruption.
• The company's ability to attract and retain a skilled and diverse workforce is important.
• The company is subject to legal proceedings and regulatory investigations.
• Concerns about the reliability, safety, and efficacy of the company's products could result in litigation.
• The company's ability to establish, maintain, protect, and enforce intellectual property rights is important.
• The company faces risks associated with conducting business globally.
• The company may not achieve some or all of the expected benefits of the separation from Johnson & Johnson.
• The company is subject to restrictions on its business, potential tax-related liabilities, and potential tax-related indemnification obligations to Johnson & Johnson.
• The company's rebranding strategy may not achieve market acceptance.
• The company may not be able to replace necessary manufacturing operations, systems, and services when the transition services agreement and the transition manufacturing agreement with Johnson & Johnson expire or terminate.
• Certain of Johnson & Johnson's current executive officers continue to serve as the company's directors, which may create conflicts of interest.
• The company may incur indemnification obligations to Johnson & Johnson.
• Johnson & Johnson has agreed to indemnify the company for certain liabilities, but such indemnity may not be sufficient.
• An active trading market for the company's common stock may not be sustained.
• The stock price of the company's common stock may fluctuate significantly.
• The company's ability to comply with obligations associated with being a public company is important.
• The company has debt obligations that impose certain restrictions on its business.
• The company is a holding company and depends on the ability of its subsidiaries to pay dividends.
• The company cannot guarantee the payment of dividends on its common stock.

Future Outlook

Kenvue seeks to deliver sustainable profitable growth through delivering science-backed innovative products, solutions and experiences centered around consumer health.

Industry Context

This announcement reflects a continued trend of large corporations divesting non-core assets to focus on strategic priorities, as Johnson & Johnson completes its exit from the consumer health sector.

Comparison to Industry Standards

• Kenvue's performance can be compared to other major players in the consumer health industry, such as Procter & Gamble (PG), Unilever (UL), and Nestle (NSRGY).
• These companies also operate across multiple segments, including self-care, skin health, and essential health.
• Benchmarking Kenvue's revenue growth, profitability, and market share against these industry leaders will provide insights into its competitive positioning.
• For example, Procter & Gamble's health care segment reported net sales of $9.7 billion in fiscal year 2023, while Unilever's health and well-being segment reported revenues of €13.4 billion in 2023.
• Comparing Kenvue's $15.4 billion net sales in 2023 to these figures provides a sense of its relative scale.
• Additionally, comparing Kenvue's dividend policy and debt levels to those of its peers can offer insights into its financial management and shareholder returns.

Related Party Transactions

• The document details the debt-for-equity exchange between Johnson & Johnson and the debt-for-equity exchange parties, which is a related party transaction.

Stakeholder Impact

• Shareholders: The offering may cause short-term stock price volatility.
• Employees: The completion of the separation provides clarity on the company's future direction.
• Customers: The offering is not expected to have a direct impact on customers.
• Suppliers: The offering is not expected to have a direct impact on suppliers.
• Creditors: The offering is not expected to have a direct impact on creditors.

Next Steps

• Completion of the debt-for-equity exchange between Johnson & Johnson and the debt-for-equity exchange parties.
• Settlement of the secondary offering and distribution of shares to the underwriters.
• Continued monitoring of Kenvue's performance and market conditions.

Key Dates

Keywords

Kenvue, Johnson & Johnson, secondary offering, common stock, debt-for-equity exchange, underwriters, KVUE, consumer health, financial results, risk factors